The company expects a full launch for the product in Q3 of this year–as early as July–to begin releasing the early stage marketing information out, such as samples for doctors and patients.
The post TherapeuticsMD Receives FDA Approval For IMVEXXY appeared first on Investing News Network.
Original Article: TherapeuticsMD Receives FDA Approval For IMVEXXY